Company intelligence / Profile preview

Micronoma

San Diego, California, United Statesmicronoma.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Micronoma’s Oncobiota™ platform uses microbiome-driven liquid biopsy technology to detect early-stage cancers by analyzing circulating microbial nucleic acids in blood. The lead program, OncobiotaLUNG for lung cancer detection, has received FDA Breakthrough Device designation. The approach aims for high sensitivity and specificity in early-stage diagnosis. However, the scientific foundation of their core technology has faced scrutiny following a retraction of a key supporting Nature paper due to concerns about data robustness. Despite this controversy, the company remains active and continues development.

Therapeutic areas: Oncology
Modalities: Diagnostic assayLiquid biopsyMicrobial nucleic acid analysis
Industry: Molecular Diagnostics

Partnerships

NYU Grossman School of Medicine

Beyond the preview

Go deeper on Micronoma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Micronoma.

Explore the full profile